Update on ASN‐002 Nodular Basal Cell Carcinoma (nBCC) Trial and The Recruitment of US Clinical Advisors

May 3rd 2017

Overall objective response rate for medium and high dose cohorts was 100% and complete response rate (histological clearance) of 89%.

Press Release: ASN-002 Clinical Study Update

News